๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 18 Guangzhou 18 Beijing 15 Changsha 10 Hangzhou 8
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai18 Guangzhou18 Beijing15 Changsha10 Hangzhou8
All 39 locations
Target enrolment
to

Trials with a site in Guangzhou

18 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Sub-lobectomy vs Lobectomy in IIA-IIIB NSCLC After Neoadjuvant IO+Chemo
NCT07612722NSCLC
Wen-zhao ZHONG
Not applicable
585
Guangzhou
2026-05-18
Not yet open
Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases
NCT07413952NSCLC
The First Affiliated Hospital of Guangzhou Medical University
Phase 2
45
Guangzhou
2026-04-01
Recruiting
RGL-270 + ICI in Advanced NSCLC
NCT07652125NSCLC
Guangdong Association of Clinical Trials
Not applicable
40
Guangzhou
2025-10-25
Not yet open
A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors
NCT07198321Cancer, PDAC, CRC (Colorectal Cancer), NSCLC
DrugGFH276
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
450
Guangzhou
2025-09-22
Recruiting
Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI
NCT07181499NSCLC, Adjuvant Drug Therapy, EGFR
Betta Pharmaceuticals Co., Ltd.
Phase 2
28
Guangzhou, Zhuhai
2025-09
Active, closed
JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC
NCT06944470NSCLC
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
78
Guangzhou
2025-05-20
Not yet open
MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer
NCT06735508NSCLC
Guangdong Provincial People's Hospital
Phase EARLY_PHASE1
40
Guangzhou
2025-01
Active, closed
A Prospective Observational Study of Changes in Cortisol Levels After Neoadjuvant Immunotherapy and Their Prognostic Value in Patients With NSCLC
NCT07530276NSCLC
Guangdong Provincial People's Hospital
Observational
330
Guangzhou
2024-08-30
Recruiting
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
NCT06422143Non-small Cell Lung Cancer, NSCLC
Merck Sharp & Dohme LLC
Phase 3
851
Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-06-10
Not yet open
Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations
NCT06054191NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation
Sun Yat-sen University
Phase 2
40
Guangzhou
2024-02-01
Recruiting
A Study of YL202 in Selected Patients With Advanced Solid Tumors
NCT06107686NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
200
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Meizhou, Shantou, Guilin
2023-12-15
Active, closed
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC
NCT05756972NSCLC
Biotheus Inc.
Phase 2
64
Guangzhou
2023-06-26
Active, closed
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266NSCLC
AstraZeneca
Phase 3
1,350
Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hefei, Jinan, Kunming
2022-12-29
Active, closed
Lorlatinib Continuation Study
NCT05144997Non-Small-Cell Lung Cancer, NSCLC
Pfizer
Phase 4
76
Hefei, Beijing, Fuzhou, Guangzhou, Changsha, Nanjing, Changchun, Hangzhou
2021-12-28
Active, closed
Crizotinib Continuation Clinical Study
NCT05160922NSCLC, ALCL, IMT
Pfizer
Phase 4
27
Beijing, Fuzhou, Guangzhou, Changchun, Wuhou District, Hangzhou, Shanghai
2021-12-27
Active, closed
An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib
NCT04764188NSCLC
Hoffmann-La Roche
Observational
800
Changsha, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Nanning, Taiyuan
2021-05-10
Recruiting
LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer
NCT06778512Lung, Lung Cancer, Cancer, NSCLC
The First Affiliated Hospital of Guangzhou Medical University
Observational
2,500
Guangzhou
2019-06-01
Rows per page Showing 1–18 of 18
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 18 of those studies with a site in Guangzhou that also match the filters currently applied.

How many clinical trials are recruiting in Guangzhou?

6 of the 18 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 5 have not yet opened recruitment, 7 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guangzhou), 18 studies
PhaseStudiesRecruitingShare
Phase 27238.9%
Observational3116.7%
Not applicable2211.1%
Phase 32111.1%
Phase 42011.1%
Phase 1/2105.6%
Phase EARLY_PHASE1105.6%

Most active sponsors

Lead sponsors with the most studies (Guangzhou)
Lead sponsorStudiesRecruiting
Guangdong Provincial People's Hospital20
Pfizer20
Sun Yat-sen University20
The First Affiliated Hospital of Guangzhou Medical University21
AstraZeneca10
Betta Pharmaceuticals Co., Ltd.11
Biotheus Inc.10
Genfleet Therapeutics (Shanghai) Inc.10
Guangdong Association of Clinical Trials11
Hoffmann-La Roche10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.